U.S. Health Dynamics: Evolving Drug Coverage and Ebola Preparedness

U.S. employers plan to drop GLP-1 obesity drug coverage, affecting financial aspects of Novo Nordisk and Eli Lilly products. The U.S. accelerates response strategies for New World screwworm amid Ebola outbreaks in Africa. Novartis reports promising results from a trial of a muscle disease drug acquired from Avidity.

In a significant policy shift, some U.S. employers are preparing to eliminate coverage for GLP-1 obesity drugs by 2027, citing increased usage rates. This decision comes as Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo offer lower prices, only to face opposition from Business Group on Health projections.

Facing a tangible threat from the New World screwworm, the U.S. government is intensifying efforts by fast-tracking drugs and ramping up funding for control measures. Despite these efforts, challenges such as staffing cuts and tool shortages loom large, potentially impacting response effectiveness against this costly parasitic threat to the cattle industry.

In pharmaceutical news, Novartis disclosed promising outcomes from an early trial of del-brax, a drug for a rare muscle disorder. Acquired during the $12 billion Avidity deal, del-brax has shown to lower disease-related blood markers, thus strengthening Novartis's position in innovative therapeutic solutions.